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infection. Insite costs were from an interview with the Principal Investigator for Insite and the medical costs were from published literature; conservative assumptions were made. All costs were in Canadian dollars (CAD) and the price year was 2006.
Analysis of uncertainty:
The issue of uncertainty was investigated by considering different mathematical models and assumptions found in the literature.
Results
In the base case, the average annual number of HIV infections prevented was 35 (range 18 to 76, depending on the model assumptions) and this resulted in average savings of CAD 5.25 million (range 2.7 to 11.4 million). The costeffectiveness ratio was CAD 42,857 (range 19,737 to 83,333) and the benefit-to-cost ratio was 3.56 (range 1.84 to 7.74).
When considering both HIV infections and deaths prevented, the average benefit-to-cost ratio was 5.12.
In all the models considered, the benefits were higher than the costs and the benefit-to-cost ratio ranged from 3 to 8.04.
Authors' conclusions
The authors concluded that this specific supervised injection facility was an effective and efficient use of health care resources, considering its impact on both HIV infections and overdose deaths.
CRD commentary

Interventions:
The selection of the comparators appears to have been appropriate, but little information was provided on the usual care.
Effectiveness/benefits:
The clinical evidence came from selected sources, which might have been known to the authors. Limited information on the characteristics of these sources was provided and this hinders the judgement of the validity of the clinical estimates. When available, data from Canada were used and the authors usually justified their selection of source for each model input and chose conservative estimates. The benefit measures were appropriate as they were the natural outcomes of the prevention programme, but they might not be directly comparable with the benefits of other health care interventions.
Costs:
The economic viewpoint was not clearly stated, but appears to have been that of the public payer. The costs were presented as overall categories, with no breakdown of cost items. This was due to the use of published estimates and an assessment of their methods of estimation was not reported. It was not clear that a discount rate was applied, but a rate of 3% was mentioned. The methods used to estimate the cost of death were described and appear to have been appropriate.
